ExPloring efficAcy, safeTy, and adHerence oF dIsease-modifyiNg antirheumatic Drugs through trajEctoRy model: the PATHFINDER study

ENCePP Seals are no longer updated or maintained

The ENCePP field fields are retained in the display mode for reference but are no longer updated or maintained. Please be aware that the information might be outdated.

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/37113
• EU PAS number:
  EUPAS29263
• Study ID:
  37113
• Official title and acronym:
  ExPloring efficAcy, safeTy, and adHerence oF dIsease-modifyiNg antirheumatic Drugs through trajEctoRy model: the PATHFINDER study
• DARWIN EU® study:
  No
• Study countries:
  Italy
• Study description:
  This project will evaluate the utilization, adherence, efficacy, and safety of disease modifying antirheumatic drugs employed for the management of rheumatoid arthritis in the Tuscan population by means of real world data. This research will identify patterns of utilization of rheumatoid arthritis treatments and their predictors, and it will explore the relationship of these trajectories with endpoints of effectiveness and safety.
• Study status:
  Planned

Research institutions and networks

Institutions

University Hospital of Pisa

Study timelines

Date when funding contract was signed

Planned: 29/03/2019

Actual: 29/03/2019

Study start date

Planned: 13/05/2019

Date of final study report

Planned: 31/12/2021

Sources of funding

Other

More details on funding

Pisa University Hospital

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable

Other study registration identification numbers and links

Protocol n.18724 of Tuscan Regional Ethics Committee for Clinical Trials